Trial Profile
A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Common variable immunodeficiency
- Focus Registrational; Therapeutic Use
- Sponsors CSL Behring
- 01 Dec 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 12 Sep 2014 New trial record